Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT6 | P42226 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.39 |
| ▸ | HSPA8 | P11142 | 1/20 | 0.39 |
| ▸ | HSPA9 | P38646 | 1/20 | 0.39 |
| ▸ | HSPA2 | P54652 | 1/20 | 0.39 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.37 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | CCKAR | P32238 | 1/20 | 0.35 |
| ▸ | PYGL | P06737 | 1/20 | 0.35 |
| ▸ | PYGM | P11217 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1931738 | 0.87 | DRD2 (0.47) | STAT6DRD2CYP51A1HRH4CNR2 | |
| SCHEMBL1931303 | 0.87 | DRD2 (0.47) | STAT6DRD2CYP51A1HRH4CNR2 | |
| SCHEMBL1931683 | 0.87 | DRD2 (0.47) | STAT6DRD2CYP51A1HRH4CNR2 | |
| SCHEMBL16474116 | 0.87 | STAT6 (0.45) | STAT6DRD2HSPA5HSPA8HSPA9 | |
| SCHEMBL1550389 | 0.85 | DRD2 (0.41) | STAT6DRD2CYP51A1HRH4CNR2 | |
| SCHEMBL19856894 | 0.85 | DRD2 (0.45) | STAT6DRD2CYP51A1HRH4CNR2 | |
| SCHEMBL19856892 | 0.85 | DRD2 (0.45) | STAT6DRD2CYP51A1HRH4CNR2 | |
| SCHEMBL1550315 | 0.85 | DRD2 (0.41) | STAT6DRD2HSPA5HSPA8HSPA9 | |
| SCHEMBL1932238 | 0.84 | DRD2 (0.40) | STAT6DRD2HSPA5HSPA8HSPA9 | |
| SCHEMBL1930560 | 0.84 | DRD2 (0.41) | STAT6DRD2HSPA5HSPA8HSPA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2925857-B1 | USE OF TRPV4 ANTAGONISTS TO AMELIORATE HYDROCEPHALUS AND RELATED MATERIALS AND METHODS | UNIV INDIANA RES & TECH CORP (US) | 2018-02-14 | — | — | EP | claimed |
| EP-2312947-B1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2014-01-01 | — | — | EP | claimed |
| US-8450484-B2 | TRPV4 antagonists | GlaxoSmithKline, LLC (US) | 2013-05-28 | — | — | US | claimed |
| US-20110130400-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC | 2011-06-02 | — | — | US | claimed |
| EP-2312947-B1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2014-01-01 | — | — | EP | disclosed |
| US-8450484-B2 | TRPV4 antagonists | GlaxoSmithKline, LLC (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450484-B2 | TRPV4 antagonists | GlaxoSmithKline, LLC (US) | 2013-05-28 | — | — | US | disclosed |
| US-20110130400-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC | 2011-06-02 | — | — | US | disclosed |
| US-20110130400-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130400-A1 | TRPV4 ANTAGONISTS | TRPV4, TRPV2, TRPV1 | STAT6 2179/4885DRD2 928/4885HSPA5 1194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.